```json
{
"content": [
{
"type": "paragraph",
"content": "The Faecal Calprotectin Testing market focuses on non-invasive diagnostic methods to detect gastrointestinal inflammation, primarily for diagnosing inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS). Faecal Calprotectin Testing market size is projected to exceed $150 million by 2026, reflecting a growth outlook of 6.8% CAGR during 2026–2033. This industry expansion is driven by rising prevalence of GI disorders, adoption of point-of-care (POCT) testing, and advancements in biomarker research. The market scope includes diagnostic reagents, testing kits, and automated analyzers, with key applications in hospitals, specialty clinics, and research facilities."
},
{
"type": "chart",
"chartType": "segment-stacked",
"data": {
"segments": ["Reagents", "Kits", "Instruments"],
"periods": ["2021", "2022", "2023", "2024", "2025", "2026", "2027", "2028", "2029", "2030", "2031", "2032", "2033"],
"values": [
[35, 38, 41, 45, 48, 52, 56, 60, 64, 68, 72, 76, 80], // Reagents
[25, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60], // Kits
[15, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38] // Instruments
]
}
},
{
"type": "paragraph",
"content": "The Faecal Calprotectin Testing market forecast highlights North America as the largest region (38% market share in 2025), driven by robust healthcare infrastructure and high GI disorder prevalence. Asia-Pacific is the fastest-growing region, with a 9.2% CAGR through 2033, fueled by expanding diagnostic access and rising chronic disease awareness. Key forces shaping the industry include technological shifts toward AI-integrated diagnostics and POCT devices, regulatory support for non-invasive testing, and competitive intensity among manufacturers enhancing test accuracy and cost-efficiency. Strategic partnerships and R&D investments are critical for sustaining growth in this niche but high-impact sector."
}
]
}
```
